Press release
Investigation for Investors in NASDAQ: LOGC shares over potential Securities Laws Violations by LogicBio Therapeutics, Inc.
An investigation for investors in LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares over potential securities laws violations.
Investors who purchased shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) concerning whether a series of statements by LogicBio Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Cambridge, MA based LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. On February 10, 2020, post-market, LogicBio Therapeutics, Inc announced that "the U.S. Food and Drug Administration (FDA) has placed a clinical hold on [LogicBio's] Investigational New Drug (IND) submission for LB-001 for the treatment of methylmalonic acidemia (MMA) pending the resolution of certain clinical and nonclinical questions."
Shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) declined from $11.60 per share on February 10, 2020 to as low as $6.99 per share on February 11, 2020.
Those who purchased shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation for Investors in NASDAQ: LOGC shares over potential Securities Laws Violations by LogicBio Therapeutics, Inc. here
News-ID: 1938177 • Views: …
More Releases from Shareholders Foundation
Investigation announced for Investors in The Estée Lauder Companies Inc. (NYSE: …
An investigation was announced on behalf of current long-term investors in shares of The Estée Lauder Companies Inc. (NYSE: EL) concerning potential breaches of fiduciary duties by certain directors of The Estée Lauder Companies Inc..
Investors who are current long term investors in The Estée Lauder Companies Inc. (NYSE: EL) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a…
Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares should contact the Sha …
The Shareholders Foundation, Inc. announces an update in the lawsuit that is pending for certain investors in Ocugen, Inc. (NASDAQ: OCGN) shares.
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) prior to May 2020 and continue to hold any of those NASDAQ: OCGN shares have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On April 1, 2024, Ocugen, Inc. filed a…
Investigation announced for Investors in shares of LuxUrban Hotels Inc. (NASDAQ: …
An investigation was announced for investors in shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) concerning potential breaches of fiduciary duties by certain directors and officers of LuxUrban Hotels Inc.
Investors who are current long term investors in LuxUrban Hotels Inc. (NASDAQ: LUXH) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
Investors who lost money with shares of Liquidia Corporation (NASDAQ: LQDA) shou …
An investigation was announced over potential securities laws violations by Liquidia Corporation in connection with certain financial statements.
Investors who purchased shares of Liquidia Corporation (NASDAQ: LQDA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Liquidia Corporation (NASDAQ: LQDA) concerning whether a series of statements…
More Releases for LogicBio
Globally, 5+ Key Companies are Actively Working in the Methylmalonic Academia Pi …
"Methylmalonic Academia Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Methylmalonic Academia Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products…
The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predi …
With multiple approved products, the field of gene therapies has gained substantial momentum over the last couple of decades; innovator companies are gradually progressing their proprietary therapy candidates with cautious optimism
Roots Analysis is pleased to announce the publication of its recent study, titled, “Gene Therapy Market (3rd Edition), 2019-2030”.
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html
The report features an extensive study of the current market landscape of…
The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predi …
With multiple approved products, the field of gene therapies has gained substantial momentum over the last couple of decades; innovator companies are gradually progressing their proprietary therapy candidates with cautious optimism
Roots Analysis is pleased to announce the publication of its recent study, titled, “Gene Therapy Market (3rd Edition), 2019-2030”.
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html
The report features an extensive study of the current market landscape of…
The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predi …
With multiple approved products, the field of gene therapies has gained substantial momentum over the last couple of decades; innovator companies are gradually progressing their proprietary therapy candidates with cautious optimism
Roots Analysis is pleased to announce the publication of its recent study, titled, “Gene Therapy Market (3rd Edition), 2019-2030”.
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html
The report features an extensive study of the current market landscape of…
Investigation announced for Investors in shares of LogicBio Therapeutics, Inc. ( …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of LogicBio Therapeutics, Inc..
Investors who are current long term investors in LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LOGC stocks follows a lawsuit filed against LogicBio…
Deadline on May 18th upcoming in Lawsuit for Investors in LogicBio Therapeutics, …
A deadline is coming up on May 18, 2020 in the lawsuit filed for certain investors of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) over alleged securities laws violations by LogicBio Therapeutics, Inc.
Investors who purchased shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) have certain options and there are strict and short deadlines running. Deadline: May 18, 2020. NASDAQ: LOGC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
